BC's Health Ministry announced it will limit the off-label use of two diabetes drugs.They reason the decision prioritizes use for diabetics.Sale limits will be placed on both tirzepatide and dulaglutide, known by the commercial names Mounjaro and Trulicity. This follows previous regulations from 2023 limiting sales of semaglutide, or Ozempic. .BC Health Minister Josie Osborne says the drugs' use for weight loss is driving shortages in the US. This rule also means the drugs cannot be sold to those who are not Canadian citizens or permanent residents in Canada. The drug also must be collected in person at a pharmacy. Minister Osborne says if non-residents and foreign citizens already have a valid prescription can still buy it in person.
